China
· Delayed Price · Currency is CNY Shenzhen New Industries Biomedical Engineering Statistics
Total Valuation
Shenzhen New Industries Biomedical Engineering has a market cap or net worth of CNY 48.64 billion. The enterprise value is 46.05 billion.
| Market Cap | 48.64B |
| Enterprise Value | 46.05B |
Important Dates
The next estimated earnings date is Friday, April 18, 2025.
| Earnings Date | Apr 18, 2025 |
| Ex-Dividend Date | May 15, 2024 |
Share Statistics
Shenzhen New Industries Biomedical Engineering has 785.72 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 785.72M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 21.83% |
| Owned by Institutions (%) | 17.41% |
| Float | 311.70M |
Valuation Ratios
The trailing PE ratio is 26.28 and the forward PE ratio is 22.10.
| PE Ratio | 26.28 |
| Forward PE | 22.10 |
| PS Ratio | 10.96 |
| PB Ratio | 5.99 |
| P/TBV Ratio | 6.18 |
| P/FCF Ratio | 45.73 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.44, with an EV/FCF ratio of 43.30.
| EV / Earnings | 24.89 |
| EV / Sales | 10.38 |
| EV / EBITDA | 21.44 |
| EV / EBIT | 23.38 |
| EV / FCF | 43.30 |
Financial Position
The company has a current ratio of 7.80, with a Debt / Equity ratio of 0.00.
| Current Ratio | 7.80 |
| Quick Ratio | 5.85 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 4,910.20 |
Financial Efficiency
Return on equity (ROE) is 24.32% and return on invested capital (ROIC) is 16.17%.
| Return on Equity (ROE) | 24.32% |
| Return on Assets (ROA) | 14.87% |
| Return on Invested Capital (ROIC) | 16.17% |
| Return on Capital Employed (ROCE) | 23.91% |
| Revenue Per Employee | 1.69M |
| Profits Per Employee | 704,431 |
| Employee Count | 2,627 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.15% in the last 52 weeks. The beta is -0.41, so Shenzhen New Industries Biomedical Engineering's price volatility has been lower than the market average.
| Beta (5Y) | -0.41 |
| 52-Week Price Change | -14.15% |
| 50-Day Moving Average | 65.87 |
| 200-Day Moving Average | 67.91 |
| Relative Strength Index (RSI) | 41.24 |
| Average Volume (20 Days) | 3,577,488 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shenzhen New Industries Biomedical Engineering had revenue of CNY 4.44 billion and earned 1.85 billion in profits. Earnings per share was 2.36.
| Revenue | 4.44B |
| Gross Profit | 3.23B |
| Operating Income | 1.97B |
| Pretax Income | 2.11B |
| Net Income | 1.85B |
| EBITDA | 2.14B |
| EBIT | 1.97B |
| Earnings Per Share (EPS) | 2.36 |
Balance Sheet
The company has 2.59 billion in cash and 4.54 million in debt, giving a net cash position of 2.58 billion or 3.29 per share.
| Cash & Cash Equivalents | 2.59B |
| Total Debt | 4.54M |
| Net Cash | 2.58B |
| Net Cash Per Share | 3.29 |
| Equity (Book Value) | 8.12B |
| Book Value Per Share | 10.33 |
| Working Capital | 4.07B |
Cash Flow
In the last 12 months, operating cash flow was 1.45 billion and capital expenditures -385.70 million, giving a free cash flow of 1.06 billion.
| Operating Cash Flow | 1.45B |
| Capital Expenditures | -385.70M |
| Free Cash Flow | 1.06B |
| FCF Per Share | 1.35 |
Margins
Gross margin is 72.86%, with operating and profit margins of 44.40% and 41.72%.
| Gross Margin | 72.86% |
| Operating Margin | 44.40% |
| Pretax Margin | 47.60% |
| Profit Margin | 41.72% |
| EBITDA Margin | 48.31% |
| EBIT Margin | 44.40% |
| FCF Margin | 23.98% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.62%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 1.62% |
| Dividend Growth (YoY) | 42.86% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 42.51% |
| Buyback Yield | 0.01% |
| Shareholder Yield | 1.63% |
| Earnings Yield | 3.80% |
| FCF Yield | 2.19% |
Stock Splits
The last stock split was on May 21, 2021. It was a forward split with a ratio of 1.9.
| Last Split Date | May 21, 2021 |
| Split Type | Forward |
| Split Ratio | 1.9 |
Scores
Shenzhen New Industries Biomedical Engineering has an Altman Z-Score of 48.89.
| Altman Z-Score | 48.89 |
| Piotroski F-Score | n/a |